Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419015 | 0.89 | KCNH3 (0.47) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11675736 | 0.89 | ALDH1A1 (0.57) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12258273 | 0.88 | MAPT (0.42) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9335414 | 0.88 | TSHR (0.45) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11677276 | 0.87 | ALDH1A1 (0.55) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6107307 | 0.86 | NAAA (0.47) | TSHRALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL3248804 | 0.85 | ALDH1A1 (0.61) | L3MBTL1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL417840 | 0.85 | LMNA (0.47) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10758749 | 0.84 | TDP1 (0.48) | TSHRL3MBTL1MAPTSMN1; SMN2HTT | |
| SCHEMBL12258272 | 0.84 | ALDH1A1 (0.39) | TSHRL3MBTL1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| CN-103179991-B | In vivo imaging method for cancer | 通用电气健康护理有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| EP-2618850-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| CN-103179991-A | In vivo imaging method for cancer | GE HEALTHCARE LTD | 2013-06-26 | — | — | CN | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| US-4060544-A | COUPLERS | GAF CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-4039524-A | Keto-amido containing phenylazo benzothiazole dyestuffs | GAF CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
| US-3931145-A | POLYESTER | GAF CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSHR 2384/4885L3MBTL1 4359/4885ALDH1A1 2535/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | TSHR 2312/4885L3MBTL1 2231/4885ALDH1A1 2183/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | TSHR 2384/4885L3MBTL1 4359/4885ALDH1A1 2535/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | TSHR 1192/4885L3MBTL1 3485/4885ALDH1A1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.